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myotubes
Brita N Che1, Niels Oksbjerg1, Lars I Hellgren2, Jacob H Nielsen3 and Jette F Young1*
Abstract
Background: Phytanic acid (PA) is a chlorophyll metabolite with potentials in regulating glucose metabolism, as it
is a natural ligand of the peroxisome proliferator-activated receptor (PPAR) that is known to regulate hepatic
glucose homeostasis. This study aimed to establish primary porcine myotubes as a model for measuring glucose
uptake and glycogen synthesis, and to examine the impact of physiological amounts of PA on glucose uptake and
glycogen synthesis either alone or in combination with insulin.
Methods: Porcine satellite cells were cultured into differentiated myotubes and tritiated 2-deoxyglucose (2-DOG)
was used to measure glucose uptake, in relation to PA and 2-DOG exposure times and also in relation to PA and
insulin concentrations. The MIXED procedure model of SAS was used for statistical analysis of data.
Results: PA increased glucose uptake by approximately 35%, and the presence of insulin further increased the
uptake, but this further increase in uptake was non- additive and less pronounced at high insulin concentrations.
There was no effect of PA alone on glycogen synthesis, while the insulin stimulation of glycogen was increased by
20% in the presence of PA. PA neither stimulated glucose uptake nor glycogen synthesis in insulin-resistant
myotubes generated by excess glucose exposure.
Conclusions: Primary porcine myotubes were established as a model of skeletal muscles for measuring glucose
uptake and glycogen synthesis, and we showed that PA can play a role in stimulating glucose uptake at no or
inadequate insulin concentrations.
Keywords: Phytanic acid, Palmitic acid, Insulin, Glucose uptake, Glycogen synthesis, Viability, Primary porcine
myotubes, Excess glucose, Free fatty acids
Background
Due to its high concentration of saturated fatty acids,
dairy fat intake has been associated with increased risk
of cardiovascular diseases and type 2 diabetes in humans
[1,2]. However, recent meta-analysis of data from pro-
spective cohort-studies shows an inverse association
between intake of dairy products and the incidence of
both cardiovascular diseases and type 2 diabetes [3], and
available data do not indicate any increased risk of high-
fat dairy products compared to low-fat dairy products
[4]. Similarly, studies using the odd-chained fatty acids
C15:0 and C17:0 as validated biomarkers of dairy fat
intake showed that a higher intake of dairy fat was asso-
ciated with a decreased risk of myocardial-infarction and
development of the metabolic syndrome [5-8]. These
findings suggest the existence of a milk-fat paradox;
despite the saturated profile of milk-fat, it does not seem
to increase metabolic risks, but might actually be pro-
tective. Hence, further research is necessary to elucidate
this controversy and to identify potential components
in dairy fat that might be responsible for the pro-
tective effect.
Milk is a very rich source of potentially bioactive lipids
such as short-chained fatty acids and conjugated linoleic
acid (CLA) [9,10]. Another fatty acid of interest in milk
is phytanic acid (PA); a C20 saturated fatty acid with
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four methyl-branches, which is known to be a natural
ligand of the nuclear receptors peroxisome proliferator-
activated receptors (PPAR) and retinoid-X- receptors
(RXR) [11-13]. The PPARs are lipid sensors, which act
by regulating body glucose and lipid homeostasis [14],
and it has been shown that PA enhances glucose uptake
in rat hepatocytes, possibly in a PPAR-dependent man-
ner, at least at high concentrations [15]. Based on these
observations, it was suggested that PA might improve
glucose- homeostasis, and thereby protect against the
development of the metabolic syndrome [16]. Dairy pro-
ducts or meat from ruminants are major sources of PA
in the human diet [17]. The concentration of PA in
plasma from healthy humans vary between 0.04 and
11.5 μM [18], and is strongly dependent on the intake of
ruminant products [19].
Skeletal muscle fibers are the major site for insulin-
regulated glucose uptake, accounting for over 70% of
glucose disposal after a meal [20]. Furthermore, excess
glucose and free fatty acid exposure lead to insulin re-
sistance in these muscle fibers [21,22]. Hence, effects of
PA on skeletal muscle glucose metabolism are expected
to have an impact on total glucose homeostasis at the
organism level. The main aim of this study was therefore
to establish primary porcine myotubes as a model for
glucose uptake and glycogen synthesis, and to examine
whether physiological concentrations of PA can alter
glucose uptake and the rate of glycogen synthesis in
primary porcine myotube cultures, either alone or in
combination with insulin.
Results
Viability assay
Primary porcine myotubes were incubated with doses of
PA ranging from 1–500 μM (Table 1). The viability of
the myotubes was not affected by 1–10 μM PA. Expos-
ure of the myotubes to 20 μM PA markedly reduced
their viability by about 20%. This viability dropped by
36% after exposure to 500 μM PA. For comparative rea-
sons, the effect of palmitic acid (PAM) on viability was
also assayed (Table 1). Exposure of myotubes to 1 or
10 μM PAM had no effect on viability while 50 μM
PAM reduced their viability by about 15% and by
500 μM PAM the viability of the myotubes were reduced
to only 54%.
Optimization in relation to glucose uptake assay
Glucose uptake in primary porcine myotubes was
insulin-dose-dependent (Figure 1a). At 0.1 nM insulin, a
significant increase in glucose uptake was recorded and
at a supraphysiological concentration of 500 nM insulin,
a 70% increase in uptake was obtained. To verify the
presence of carrier-mediated glucose uptake in the
primary porcine myotube model, different doses of
cytochalasin B (cyto B) (0–50 μM) were added to the
differentiated myotubes (Figure 1b). At 10 μM cyto B,
glucose uptake in myotubes with and without insulin
was reduced to 54 and 40%, respectively, when com-
pared to that of control cells without insulin or cyto B
addition. In the presence of 20–50 μM cyto B, the glu-
cose uptake was reduced to approximately 70-90% of
controls without cyto B, irrespective of insulin addition.
Glucose uptake as a function of PA incubation time and
2-DOG incubation time
Based on the results from the viability studies and the
concentration profile of PA in human plasma, glucose
uptake assays were performed in myotubes that were
incubated with 10 μM PA over a period of 24 h to define
an effective incubation time with PA (Figure 2a). No sig-
nificant increase in glucose uptake was observed after
1 h incubation with PA. There was, however, a tendency
of elevated glucose uptake between 4–8 h of incubation
with PA followed by a temporary marked decrease be-
tween 12–16 h of incubation, when compared to 1 h of
incubation.
To estimate an optimal incubation time for 2-DOG to
achieve effective uptake, myotubes were exposed to 2-
DOG for 5–60 min with or without 10 μM PA
(Figure 2b). There was a general steady increase in glu-
cose uptake with increasing time of incubation with 2-
DOG. The steepest increase in 2-DOG uptake was
observed during the first 15 min, while the process was
slowest during the last 10 min of incubation. In the pres-
ence of PA, glucose uptake tended to be higher at all the
Table 1 Effect of fatty acids on the viability of primary
porcine myotubes
Fatty acid
concentration
(μM)
Fold change in viability
PA PAM
Control (0) 1a ± 0.023 1a ± 0.036
1 1.01a ± 0.030
10 0.97a ± 0.022 0.95a ± 0.031
20 0.81b ± 0.036
50 0.74bc ± 0.042 0.85b ± 0.032
100 0.70c ± 0.046 0.82b ± 0.035
200 0.74c ± 0.029
300 0.61d ± 0.051
500 0.64c ± 0.025 0.54d ± 0.030
Differentiated porcine myotubes were incubated with different concentrations
of fatty acids (PA or PAM) for 24 h, and then treated with WST-1 reagent as
mentioned in the methods. Control samples contained experimental media
without fatty acids. Data are expressed as LSmean values from five-eight
replicate wells, carried out in three separate experiments with cells isolated
from a different pig each time. LSmeans with different letters (a-d) within each
row denote significantly different responses related to fatty acid
treatments; (P < 0.05).
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different incubation times, but this difference was sig-
nificant only after 60 min of incubation with 2-DOG.
Glucose uptake in response to PA and PAM
When testing the effect of PA on glucose uptake (Table 2),
a 23% increase in uptake was noted even at the sub-
physiological concentration of 0.5 μM PA. Increasing the
PA concentration further did not significantly increase the
uptake, although average uptake increased to between 30-
35%. The effect of 1–10 μM PA could not be mimicked by
same concentrations of PAM (Table 2). However, when
myotubes were exposed to higher doses of PAM, there
were marked changes in glucose uptake. Glucose uptake
dropped to 75% when the myotubes were exposed to
100 μM PAM and at 200 μM and 400 μM PAM, the glu-
cose uptake ability of the myotubes was only 50% and
30%, respectively, when compared to controls.
Glucose uptake and glycogen synthesis with or without
PA as a function of insulin
The impact of PA on glucose uptake and glycogen syn-
thesis was also studied in relation to various insulin
Insulin concentration (nM)
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Figure 1 Glucose uptake in porcine myotubes in response to insulin and cyto B. Glucose uptake was performed on differentiated porcine
myotubes in the presence of varying concentrations of insulin (a), or varying concentrations of cyto B with (full circles) or without (open circles)
500 nM insulin (b). Control samples lacked cyto B. Data are expressed as LSmean values of four replicate wells, carried out in at least two separate
experiments with cells isolated from a different pig each time. * denotes LSmeans with significant difference in responses with or without
insulin; (P < 0.05).
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concentrations. Addition of 10 μM PA caused a further
increase in glucose uptake at all levels of insulin
(Figure 3a), but a significant improvement was only
achieved at lower insulin concentrations (0 and 0.1nM).
The incorporation of glucose into glycogen increased in
response to insulin treatment from 0–100 nM, with
a significant increase at 10 and 100 nM insulin
(Figure 3b). Overall, glycogen synthesis was not signifi-
cantly affected by PA alone, regardless of the increased
tendency. However, in the presence of 10 nM insulin,
PA caused an additional increase in glycogen synthesis
of about 20%.
Exposure of myotubes to extracellular glucose
The viability of the myotubes after exposure to excess glu-
cose (12 mM) was not significantly affected (Figure 4a).
The addition of 7, 10 and 15 mM of extracellular glucose
reduced glucose uptake to about 80, 65 and 23%,
PA incubation time (h)
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Figure 2 Glucose uptake with or without PA as a function of 2-DOG incubation time. Glucose uptake was performed on differentiated
myotubes that had been incubated with (a) 10 μM PA for different times and then treated with 2-DOG for 30 min, or (b) with (full circles) or
without (open circles) 10 μM PA for 4 h and afterwards treated with 2-DOG for 5–60 min. Data are expressed as LSmean values of triplicate wells
carried out in three separate experiments with cells isolated from a different pig each time. LSmeans with different letters (a-e) denote
significantly different responses related to incubation times, while * denotes LSmeans with significantly different responses with or without
PA; (P < 0.05).
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respectively, when compared to myotubes exposed to only
4 mM of extracellular glucose (Figure 4b). Higher
amounts of extracellular glucose did not cause further
drops in glucose uptake. While 10 μM PA and 10 nM in-
sulin caused an approximate 40 and 75% increase, respect-
ively, in glucose uptake in myotubes exposed to 6 mM
extracellular glucose, no effect of neither PA nor insulin
was observed when myotubes were exposed to 14 mM
extracellular glucose (Figure 4c). Glycogen synthesis was
reduced to 25% when myotubes were treated with 14 mM
glucose, compared to myotubes treated with 6 mM glu-
cose (Figure 4d). The marked effect of 10 nM insulin on
glycogen synthesis in the presence of 6 mM glucose was
abolished by exposing the myotubes to 14 mM glucose
(Figure 4d).
Discussion
Phytanic acid (PA) is a natural ligand and activator of
the PPARs, specifically PPAR-α and γ [23]. The
PPARs have been implicated not only in the regula-
tion of adipose tissue development and insulin signal-
ing [24] but also in modulating insulin sensitivity of
muscles [25,26] and increasing exercise endurance
[27]. It has been hypothesized that PA can function
as a natural PPAR agonist and therefore, be useful in
the prevention and treatment of diabetes [28]. Hence,
PA may have a positive influence on the regulation of
glucose metabolism. As skeletal muscle is the major
site of insulin-dependent glucose uptake [20], we
established a primary myotube model to study the
effect of PA on glucose-homeostasis. The porcine
primary myotube model shares many similarities to
the human myocytes and has fewer artifacts when
compared to immortal cell line systems [29]. Satellite
cells were grown into myoblasts (Figure 5a and c)
and successfully differentiated into characteristic mul-
tinucleated myotubes (Figure 5b and d), just as in
previous findings [30].
Initially, the suitability of the primary porcine myotube
model was tested, and assay conditions optimized in rela-
tion to both glucose assay compound (2-DOG) and PA ex-
posure. Viability assays were performed to determine an
appropriate concentration of PA that did not compromise
the cells metabolic activities. The viability of the myotubes
was noticeably reduced when exposed to concentrations
of PA equal to or above 20 μM (Table 1). The toxic effect
of PA at 20 μM or above may be attributed to apoptosis of
the cells, as shown previously by studies in human skin
fibroblasts and rat liver [31,32]. The average concentration
of PA in human plasma has been reported to be between
0.04-11.5 μM [18,19,33], with higher values found pre-
dominantly in meat eaters and dairy product consumers
[18,19]. Based on this, and the results from our viability
studies, the working concentration of PA was chosen as
10 μM. Palmitic acid (PAM); a fatty acid of same chain
length as PA but without the branching methyl-groups
was used as a control, and we showed that 1 and 10 μM
PAM had no effect on myotube viability. At concentra-
tions of 50 μM PAM and above, the viability of the myo-
tubes were reduced, possibly in a manner similar to that
of higher amounts of PA [31,32].
The non-metabolizable analogue of glucose; 2-
deoxyglucose (2-DOG), is a suitable marker for the
measurement of muscle glucose transport as it can be
transported into cells just like glucose [34], and it was
used in this study to measure glucose uptake. Glucose
transport in muscles is insulin-dependent and mediated
by GLUT-4 transporters, as well as insulin-independent,
mediated by GLUT-1 transporters [35]. Insulin treatment
of varying concentrations caused a dose-dependent increase
in glucose uptake in the myotubes (Figure 1a), proving that
the primary porcine myotubes have a functional insulin-
stimulated GLUT-4 translocation to the plasma membrane
[36]. The action of both GLUT-1 and GLUT-4 in the
carrier-mediated glucose uptake was checked by treatment
of the myotubes with cytochalasin B (cyto B); a drug known
to inhibit glucose transport by binding to glucose transpor-
ters with a higher affinity than glucose [37,38]. From our
observation, cyto B inhibited both the insulin- and non-
insulin-mediated glucose uptake to a similar magnitude in
primary porcine myotubes (Figure 1b). The reduction in
glucose uptake by cyto B confirms that both the insulin-
and the non-insulin-mediated transport systems are func-
tional in our primary porcine myotube model. Our
observation with cyto B also showed that about 20% of
Table 2 Glucose uptake in response to PA and PAM
Fatty acid
concentration
(μM)
Glucose uptake
PA PAM
Control (0) 1.00a ± 0.045 1.00a ± 0.067
1 1.23b ± 0.105 1.09a ± .051
5 1.29b ± 0.071
10 1.32b ± 0.075 1.14a ± 0.061
20 1.34b ± 0.166
40 1.37b ± 0.076
50 0.92a ± 0.032
60 1.37b ± 0.079
100 0.75b ± 0.032
200 0.48c ± 0.04
400 0.32d ± 0.028
Glucose uptake was carried out on differentiated myotubes that had been
incubated with 1–60 μM PA or 1and 10 μM PAM for 4 h. PAM from 50–
400 μM was administered for 24 h. Control samples lacked fatty acids. Data
are expressed as LSmean values of triplicate wells, carried out in three
separate experiments with cells isolated from a different pig each time.
LSmeans with different letters (a-d) within each row denote significantly
different responses related to fatty acid treatments; (P < 0.05).
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glucose uptake in the myotubes was not affected by cyto B.
One can speculate that a minimal steady state of non-
specific glucose uptake is maintained in the porcine cul-
tures. It is also likely that other GLUT receptors than
GLUT 1 and 4 are present in the myotubes [39], and cyto
B cannot bind to them. In that case glucose transport is
possible even in the presence of cyto B.
A biphasic effect on glucose uptake was observed
during the 24 h incubation of myotubes with 10 μM
PA (Figure 2a). Since only a subtle increase in glucose
Insulin concentration(nM)
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Figure 3 Glucose uptake and glycogen synthesis with or without PA as a function of insulin. Glucose uptake (a) was carried out on
differentiated myotubes that had been incubated with (full circles) or without (open circles) 10 μM PA for 4 h, followed by different
concentrations of insulin during the last 1 h. Glycogen syntheses (b) were performed on myotubes treated with (full circles) or without (open
circles) 10 μM PA for 4 h, followed by 0–100 nM insulin for 2 h. Control samples lacked PA and insulin. Data are expressed as LSmean values
collected from three-four wells, carried out in three separate experiments with cells isolated from a different pig each time. LSmeans with
different letters (a-d) denote significantly different responses related to the insulin concentration, while * denotes LSmeans with significantly
different responses with or without PA; (P < 0.05).
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uptake was noticed after 4 and 8 h exposure to PA, it
is less likely that the subsequent fall in glucose uptake
is due to depletion of GLUT depots. Other unknown
factors could, thus, be responsible for this drop in
glucose uptake. A rise in glucose uptake at 24 h
could be linked to consequent up-regulation of tran-
scripts responsible for the translation of proteins that
skew up glucose uptake.
Glucose uptake has been shown to be linear for
over 20 min in a human skeletal muscle cell line
study [40], and in the present study, the steepest in-
crease in glucose uptake was observed during the first
15 min of incubation with 2-DOG and by 45 min,
the curve started to level off (Figure 2b). It is possible
that after 45 min incubation with 2-DOG, a partial
saturation of the normal glucose pathway is attained.
Following these observations, the incubation time
with 2-DOG was set at 30 min.
Considering the effects of PA on glucose uptake, it
is noteworthy that a concentration as low as 1 μM
caused a 25% increase in glucose uptake. Increasing
the PA concentration to 10 μM slightly increased glu-
cose uptake further (Table 2), while equivalent
amounts of PAM had no effect on glucose uptake.
The effect of PA was, thus, a specific effect, which is
in agreement with a similar study in rat hepatocytes,
in which 100 μM PA markedly increased glucose up-
take following incubation with 2-DOG, when com-
pared to docosahexaenoic acid [15]. The reduction in
glucose uptake observed at PAM concentration of
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Figure 4 Exposure of myotubes to extracellular glucose. Differentiated myotubes treated with two different concentrations of glucose for
24 h were subjected to viability assay (a). Glucose uptake was also performed on myotubes exposed to various glucose concentrations (b).
Myotubes exposed to 6 mM glucose (controls) or 14 mM glucose for 24 h in the absence (open bars) or presence of PA (black bars) or insulin
(grey bars) were subjected either to (c) glucose uptake or (d) glycogen synthesis measurements. PA was administered for 24 h while insulin was
given during the last 1 h of incubation for glucose uptake measurements and 2 h for glycogen synthesis. Data are expressed as LSmean values of
four replicate wells, carried out in three separate experiments with cells isolated from a different pig each time. LSmeans with different letters (a
and b) denote significantly different responses related to PA or insulin treatments, while statistical difference in LSmeans between controls and
myotubes given 14 mM glucose is denoted with *; (P < 0.05).
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over 100 μM (Table 2) was partly due to inhibition of
glucose transport activity [41], but also most likely a
consequence of stress [31].
The effect of PA diminished with increasing insulin
stimulation of glucose uptake (Figure 3a). This could
indicate a similar mode of action between insulin and
PA. Our results also indicate that the PA concentra-
tions normally found in plasma (> 1 μM), are suffi-
cient to enhance non-insulin dependent glucose
uptake and that alteration of plasma PA concentra-
tions within normal physiological range, only have
minor effects. Hence, we suggest that normal levels of
PA is a relevant factor in controlling fasting glucose
homeostasis in vivo and that increased intake of PA
only will affect glucose uptake in subjects with ex-
tremely low PA-levels (for example strict vegetarians
with no intake of dairy products or ruminant meat).
Despite the fact that 10 μM PA induced an
increased glucose uptake in the absence of insulin
(Figure 3a), it did not enhance the rate of glycogen
synthesis (Figure 3b). Thus, PA at physiological con-
centrations increases glucose uptake in the absence of
insulin, without causing a concomitant increase in
glycogen synthesis, why the absorbed glucose must be
shunted into other metabolic pathways. However, the
combination of 10 μM PA and 10 nM insulin more
than doubled the rate of glycogen synthesis, com-
pared to the effect of insulin alone (45% vs. 20%).
This creates a somewhat paradoxical situation that in-
creasing insulin concentrations attenuate the effect of
PA on glucose uptake, but enhance its effect on
glycogen synthesis. Hence, the two effects must be
explained by different mechanisms of action of PA. It
should be noted, that the effect of PA on both glu-
cose uptake and glycogen synthesis is not a general
effect of fatty acids, as the same concentration of
PAM did not cause these effects, neither with nor
without insulin (data not shown).
Previous studies have shown that excess glucose
causes glucose toxicity that is manifested by the inhi-
bition of glucose uptake and induction of insulin resis-
tance in the muscles [42]. The toxicity of excess glucose
is due to the activation of the hexamine pathway
and production of glucosamine, which inhibits insulin-
stimulated glucose uptake and subsequently glycogen
synthesis [43]. Our observations that increasing amounts
of glucose inhibit glucose uptake (Figure 4b and c) and
glycogen synthesis (Figure 4d) are in agreement with
a  
c  
b
d
Figure 5 Microscopic view of proliferating and differentiating porcine satellite cells. Proliferating myoblasts at 80% confluence (a) or
myotubes at day 2 of differentiation (b) were stained as described in the methods to reveal the single nuclei cells of myoblasts (c) and multi-
nuclei tubular structure of myotubes (d). Picture magnification was 100 x.
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these findings. Excess glucose did not affect the viability
of the myotubes (Figure 4a), ruling out the possibility
that the fall in glucose uptake was due to decreased
viability of the myotubes. These findings stress the
role of excess glucose in generating insulin resistance;
it is therefore also noteworthy that neither PA nor in-
sulin had any effect on glucose uptake or glycogen
synthesis in myotubes that had been exposed to ex-
cess glucose.
Conclusion
In the present study, we have been able to generate a
suitable primary porcine cell model for studying both
insulin and non- insulin-stimulated glucose uptake at
physiological levels of insulin, as 0.1 nM insulin
induces a significant increase in glucose uptake. We
have shown that PA alone can improve glucose up-
take but not glycogen synthesis and that during glu-
cose uptake, PA probably competes with insulin in
insulin-signaling. PA can neither stimulate glucose up-
take nor glycogen synthesis in insulin-resistant cells
generated by exposure to excess glucose. A potential
role for PA may, thus, be stimulating glucose uptake
in muscle cells at inadequate insulin concentrations,
although the consequences of increasing glucose up-
take without a concomitant increase in glycogen syn-
thesis need to be studied further.
Methods
Materials and reagents
Human insulin, PA, PAM, dimethyl sulfoxide (DMSO),
cyto B, essentially fatty acid-free bovine serum albumin
(defatted BSA), glycogen, haematoxylin, chloral hydrate,
cytosine arabinoside and antibiotics were all purchased
from Sigma. Dulbecco’s Modified Eagle’s Medium
(DMEM), fetal bovine serum (FBS), horse serum (HS)
and phosphate buffered saline (PBS) were obtained from
Life Technology. The WST-1 reagent was obtained from
Boehringer Mannheim. Matrigel reagent was from Bec-
ton Dickinson, and the BCA kit was from Pierce
Rockford. [1-3H] - 2-DOG was purchased from GE
Healthcare and [1-14C]-D-glucose from PerkinElmer.
Buffers and media
The proliferation growth media (PGM) consisted of
DMEM containing 22 mM D-glucose, 10% FBS, 10%
HS, 1% penicillin-streptomycin, 1.2% amphotericin B
and 0.2% gentamycin. The first differentiation media
(DM1) was as PGM but without HS and D-glucose was
reduced to 6 mM. The second differentiation media
(DM2) was as DM1, except for a reduction of FBS to 5%
and addition of cytosine arabinoside to stop prolifera-
tion. The third differentiation media (DM3) was as DM2
but lacked serum. Hepes-buffered saline (HBS) pH 7.4
consisted of 20 mM Hepes, 140 mM NaCl, 5 mM KCl,
2.5 mM MgSO4 and 1 mM CaCl2. The storage medium
was made up of PGM and 10% DMSO. Haematoxylin
solution (100 mL) consisted of 5 g hydrated potassium
sulphate, 0.01 g sodium iodate, 0.1 g haematoxylin dye,
5 g chloral hydrate and 0.1 g acetic acid to improve
shelf-life of the solution.
The experimental media normally consisted of the
stock media (2.5 mM D-glucose and defatted BSA)
but where indicated, included different doses of insu-
lin and/or glucose and fatty acids. Fatty acids were
solubilized either in DMSO or ethanol. Ethanol was
evaporated under a stream of liquid nitrogen while
the final amount of DMSO in the experimental media
was less than 0.1%. The experimental media with fatty
acid was sterilized using a sterile filter and left over-
night at room temperature to ensure efficient binding
of defatted BSA to the free fatty acids. In this study,
the fatty acid: BSA ratio was limited to 5:1. The
amount of glucose, DMSO and defatted BSA in con-
trol samples was equivalent to that of treated sam-
ples, unless stated otherwise.
Media for glycogen analysis consisted of 5 mM D-glu-
cose, 0.2 μCi [1-14C]-D-glucose and 0.1% defatted BSA
in HBS. Glycogen carrier stock solution consisted of
0.5 g glycogen in 50 ml 30% KOH solution.
Isolation and culture of primary porcine satellite cells
Primary satellite cells were obtained from the left semi-
membranosus muscle of six weeks-old female pigs,
weighing between 12–13.5 kg following a method
described by Theil et al. [44]. Isolated cells were placed
in storage medium and stored in liquid nitrogen until
use. Cells were thawed in a 37°C water bath and seeded
on 4% matrigel-coated plates containing PGM. After
2 days, cells were washed with 1xPBS, pH 7.4 (with
Ca2+, Mg2+) and allowed to proliferate for 3–4 days to
80% confluence (Figure 5a and c). Cells were given DM1
until 100% confluent, and thereafter DM2 was given to
stop proliferation and initiate differentiation. At this
stage, the cells were denoted to be at their first day of
differentiation. Cells were given DM2 until day 2 of dif-
ferentiation, where fully developed myotubes were
observed microscopically (Figure 5b and d). Myotubes
were given DM3 16 h prior to experimental treatment.
When the experimental treatment was administered for
more than 4 h, DM3 was omitted. Cell culturing was
performed at 37°C with 5% CO2 and at 100% humidity.
Haematoxylin staining
Cells were rinsed twice with 1xPBS (without Ca2+, Mg2+)
and fixed with ice-cold methanol for 5 min. The methanol
was replaced by haematoxylin solution for 10 min, after
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which the dye was aspirated and cells were rinsed several
times to discard unwanted stain. Cells were viewed for ap-
propriate staining on a microscope at 100 × magnification.
Viability test
After cell growth, differentiation and incubation with
experimental media for 24 h, myotubes were rinsed
with 1xPBS (with Ca2+, Mg2+) and WST-1 reagent
was used as described by Okura et al. [45]. The gen-
eration of a formazan dye by cleavage of a tetrazo-
lium salt present in the reagent reflects the amount
of active cells present in culture. The absorbance of
the culture media, which was corrected for blank
readings in the presence of medium only, was mea-
sured at A450-630 using the Envision Multilabel Plate
Reader model 2104 PerkinElmer.
Protein determination
The protein concentration of myotube samples was
determined using the bicinchroninic acid (BCA) assay as
described earlier by Smith et al. [46].
2-deoxyglucose uptake
Cells seeded in 48-well plates were cultured as
described earlier until the 2nd or 3rd day of differenti-
ation. They were rinsed once with 1xPBS, pH 7.4
(with Ca2+, Mg2+) and incubated at given time points
with experimental media (see figure legend). Cells
were washed 3 × with HBS solution, and glucose up-
take was carried out using [1-3H] 2-DOG as
described by Klip et al. [47]. Unless stated otherwise,
cells were incubated with 2-DOG for 30 min. Carrier-
dependent glucose uptake was checked using [1-3H]2-
DOG solution containing varying concentration of
cyto B [40]. Samples were assayed for [1-3H] 2-DOG-
uptake as disintegrations per min and normalized to
the basal level of glucose uptake in control samples.
Glycogen synthesis
Glycogen analysis was carried out on cells grown in 48-
well plates as described by Al-Khalili et al. [36] with
some modifications. On day 2 or 3 of differentiation,
DM3 media was replaced with experimental media. Cells
were rinsed afterwards with HBS solution and then incu-
bated with fresh HBS solution containing 0.1 mM defat-
ted BSA (and insulin where indicated) for 2 h. Media for
glycogen analysis (containing [1-14C]-D-glucose) was
added to the cells during the last 1.5 h of incubation.
Cells were washed 3 times with ice-cold 1xPBS, pH 7.4
(without Ca2+, Mg2+) and lysed with 200 μL 30% KOH
per well for at least 30 min. The cell lysate was trans-
ferred into eppendorf tubes, heated for 10 min at 96°C
and 3 mg/ml of carrier glycogen was added to the cell
lysate. A portion of the cell lysate was used for protein
determination. Glycogen was precipitated by overnight
incubation with 5 volumes of ethanol and 5% sodium
sulfate at −20°C. The precipitated glycogen was collected
by centrifugation at 20.800 × g for 5 min, and re-
dissolved in distilled water. Radioactivity was measured
in a scintillation mix as disintegrations per min and the
values were corrected to the protein content of the cells.
Statistical analysis
Statistical analyses were performed using the MIXED
procedure in SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA). The results are presented as least
square mean estimates (LSmeans) and the standard
error of mean (SEM). When the main effects were
significant, the least square mean estimates were
separated by least significant difference (p < 0.05). All
data are expressed as fold changes normalized to con-
trol samples.
Ethics approval
Pigs used for the isolation of satellite cells were trea-
ted according to the Danish Ministry of Justice Law,
no. 382 (June 10, 1987).
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